Lupus (Systemic Lupus Erythematosus) and cannabis in Pennsylvania
The state currently does not list this condition as qualifying, and the program does not provide open-ended physician discretion to add conditions. Verify with the state regulator, because programs change.
- ✗ No
- LEGAL
- 30-day supply as certif…
- POSSESSION
- $50/yr
- STATE FEE
- 7–21 d
- TIMELINE
Pennsylvania statute and program
The Pennsylvania Medical Marijuana Program is the operating authority for Pennsylvania patient certification. The authoritative legal text is: 35 P.S. §§ 10231.101 – 10231.2110: Medical Marijuana Act. The program portal is at Pennsylvania Medical Marijuana Program.
What the evidence says about cannabis and Lupus (Systemic Lupus Erythematosus)
Systemic lupus erythematosus (SLE), commonly called lupus, is a chronic autoimmune disease in which the immune system produces autoantibodies that attack the body's own tissues. Inflammation can affect joints, skin, kidneys, blood, lungs, heart, and the nervous system. Lupus is a relapsing-remitting disease — patients experience flares and periods of relative quiescence.
For the full evidence base, including the NASEM tier, randomized trial summaries, and symptom-domain breakdown, read the mmjnow Lupus (Systemic Lupus Erythematosus) page.
How to qualify in Pennsylvania
The Pennsylvania Medical Marijuana Program requires the following registration steps for a Lupus (Systemic Lupus Erythematosus) patient (or any qualifying diagnosis):
- Register through the Pennsylvania Medical Marijuana Program patient portal. Pennsylvania requires the patient to register first, before seeing a practitioner. Patients create an account at the Department of Health Medical Marijuana Program online registry using their Pennsylvania driver license or state ID. The portal assigns a patient ID number that the patient then takes to a certifying practitioner.
- Get certified by a PA-registered practitioner. A Pennsylvania-licensed physician registered with the Medical Marijuana Program must evaluate the patient for one of the enumerated serious medical conditions under 35 P.S. §10231.103 (cancer, HIV/AIDS, ALS, Parkinson’s, MS, epilepsy, glaucoma, intractable seizures, IBD, neuropathies, Huntington’s, Crohn’s, PTSD, severe chronic pain, terminal illness, sickle cell, autism, anxiety disorders, Tourette’s, dyskinetic and spastic movement disorders). The practitioner issues an electronic certification.
- Pay the $50 state ID card fee. After certification appears in the patient’s portal account, the patient pays the $50 annual identification card fee online. The fee is reduced or waived for patients on Medicaid, PACE/PACENET, CHIP, SNAP, or WIC under PA Department of Health rules.
- Receive your card and purchase from a PA dispensary. Pennsylvania medical marijuana ID cards arrive by mail within roughly 7 to 14 business days. Patients may purchase up to a 90-day supply per visit (no flower restrictions since 2018) from any Pennsylvania licensed dispensary. Cards renew annually with a new practitioner certification.
- State registration fee
- $50
- Physician visit (typical)
- $150–$250
- Certification to card
- 7–21 days
- Out-of-state patients
- Not eligible
- Minors
- Eligible with caregiver
For full Pennsylvania registration steps, fees, and reciprocity rules, see the Pennsylvania cannabis-laws page.
ICD-10 code
A certifying physician documenting Lupus (Systemic Lupus Erythematosus) for the Pennsylvania medical cannabis program will typically record ICD-10 M32.9 or SNOMED-CT 55464009 in the patient's record. The state registry does not itself collect ICD-10 codes in most programs, but the physician's chart is the audit trail if the certification is later reviewed.
Frequently asked questions
Does Pennsylvania list Lupus (Systemic Lupus Erythematosus) as a qualifying condition for medical cannabis?
No. Pennsylvania's qualifying-condition list does not currently include Lupus (Systemic Lupus Erythematosus), and the state's program does not give physicians open-ended discretion to add conditions outside the list. Patients with Lupus (Systemic Lupus Erythematosus) in Pennsylvania have limited in-state pathways under the medical program as written. Options to verify and pursue include: petitioning the state regulator to add the condition (where the statute permits public petitions); consulting a physician about whether a co-occurring listed condition could support certification; or reviewing whether the state's program is undergoing legislative expansion. Pennsylvania program rules change, so verify the current list with the regulator before drawing a final conclusion.
How do I get a Pennsylvania medical marijuana card for Lupus (Systemic Lupus Erythematosus)?
Because Pennsylvania does not currently list Lupus (Systemic Lupus Erythematosus) as a qualifying condition, a card for Lupus (Systemic Lupus Erythematosus) alone may not be obtainable in-state under the program rules as written. Step one is finding a physician licensed in Pennsylvania who is registered with Pennsylvania Medical Marijuana Program and willing to evaluate Lupus (Systemic Lupus Erythematosus) cases. Step two is collecting your records (diagnosis documentation, treatment history, and the ICD-10 code your physician will use) and bringing them to the certification visit. Step three is the physician's certification through the state registry, followed by the patient registration application, state fee, and waiting period before the card is issued. Pennsylvania does not honor out-of-state cards, so the certification process has to originate inside the state. The state minimum patient age is 18; minors generally require a parent or legal guardian to act as caregiver. The authoritative source for the current process is the Pennsylvania Medical Marijuana Program site at https://www.pa.gov/agencies/health/programs/medical-marijuana; the state updates fees, forms, and physician registration rules periodically.
What does the evidence say about cannabis for Lupus (Systemic Lupus Erythematosus)?
For Lupus (Systemic Lupus Erythematosus), evidence is described as limited (a small number of supportive studies, often underpowered or focused on narrow symptom domains). The mmjnow condition page for Lupus (Systemic Lupus Erythematosus) lays out the current evidence base, including the citations underlying that evidence tier — typically the National Academies of Sciences, Engineering, and Medicine consensus reports, federal agency guidance, and peer-reviewed reviews. Evidence quality is independent of state law: a state can list a condition for which evidence is limited, and a state can decline to list a condition for which evidence is strong. Patients deciding whether to pursue medical cannabis for Lupus (Systemic Lupus Erythematosus) should review the underlying evidence (linked on the condition page) and discuss expected benefit, dosing, and risk with a clinician familiar with both Lupus (Systemic Lupus Erythematosus) and cannabinoid pharmacology. Cannabis is not a substitute for evidence-based first-line treatments for Lupus (Systemic Lupus Erythematosus); the evidence position above describes whether trial data supports its use, not whether it should replace standard care.
Sources
- 35 P.S. §§ 10231.101 – 10231.2110: Medical Marijuana Actaccessed May 15, 2026
- PA Department of Health: Medical Marijuanaaccessed May 15, 2026
- NORML: Pennsylvania Lawsaccessed May 15, 2026
- 35 P.S. §780-113(a)(31): Possession penalties (PA Controlled Substance Act)accessed May 17, 2026
- 75 Pa.C.S. §1532(c): Driver license suspension on drug convictionaccessed May 17, 2026
- 75 Pa.C.S. §3802: Driving under the influence (DUI)accessed May 17, 2026
- Pennsylvania General Assembly bill search and trackeraccessed May 17, 2026
- City of Philadelphia Code §10-2102 (civil-citation ordinance, Bill 140377, 2014)accessed May 17, 2026
- City of Pittsburgh Code of Ordinances (Municode) — civil-citation ordinance 2015-1739accessed May 17, 2026
- City of Harrisburg Codified Ordinances (Municode) — Chapter 3-509, Ordinance 4-2014accessed May 17, 2026
- NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases: Lupusaccessed May 18, 2026
- NASEM: The Health Effects of Cannabis and Cannabinoids (2017)accessed May 18, 2026
“Substantial evidence that cannabis or cannabinoids are effective for chronic pain in adults.”
- Lupus Foundation of America: Marijuana and Lupusaccessed May 18, 2026
- American College of Rheumatology: 2023 Guideline for SLE Management (executive summary)accessed May 18, 2026
- MedlinePlus: Systemic lupus erythematosusaccessed May 18, 2026